Dispersible formulations of n-((r)-2,3-dihydroxypropoxy)-3,4-difluoro-2-(2- fluoro-4-iodo-phenylamino)-benazmide and uses thereof
US-2024216307-A1 · Jul 4, 2024 · US
US2022409538A1 · US · A1
| Field | Value |
|---|---|
| Publication number | US-2022409538-A1 |
| Application number | US-202217823750-A |
| Country | US |
| Kind code | A1 |
| Filing date | Aug 31, 2022 |
| Priority date | May 3, 2019 |
| Publication date | Dec 29, 2022 |
| Grant date | — |
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
What the patent document calls the invention.
A short plain-language summary of the technical disclosure.
Who owns or filed the patent and who is credited as inventor.
Filing, priority, publication, and grant dates set the timeline.
The legal scope of protection — read this for what is actually claimed.
Technology tags used to group this patent with similar filings.
Prior art links and similar publications in this corpus.
Official abstract text for this publication.
The invention pertains to a method for treating a neoplasm, such as colorectal cancer, using hollow silica spheres (“HSS”). It also is directed to a method for making uncalcined HSS, calcined HSS from which phenyl groups have been removed, and HSS incorporating particles of Fe3O4, as well as compositions containing HSS
Opening claim text (preview).
1 . (canceled) 2 . The method of claim 18 , wherein the hollow silica spheres are prepared by a process comprising hydrolysis of a mixture comprising Fe 3 O 4 and phenyl-tri-methoxysilane (“PTMS”) followed by condensation with a hydroxide base. 3 . The method of claim 18 , wherein the Fe—HSS are not calcined. 4 . The method of claim 18 , wherein the Fe—HSS are calcined. 5 . The method of claim 18 , wherein the surfaces of the Fe—HSS are substantially free of phenyl or aryl groups. 6 . (canceled) 7 . (canceled) 8 . (canceled) 9 . (canceled) 10 . (canceled) 11 . (canceled) 12 . (canceled) 13 . (canceled) 14 . The method of claim 18 , wherein the Fe—HSS have average diameters ranging from 415 to 615 nm. 15 . The method of claim 18 , wherein the Fe—HSS comprises Fe 3 O 4 particles having an average diameter ranging from 9.5 nm to 21.3 nm. 16 . The method of claim 15 , wherein the Fe 3 O 4 particles are crystalline and present in an amount ranging from 0.1 to 10 wt % of a combined weight of the HSS and Fe 3 O 4 in the Fe—HSS. 17 . (canceled) 18 . A method for forming hollow silica spheres incorporating Fe 3 O 4 (“Fe—HSS”) comprising: dissolving a hydrolyzable aryl silane in an aqueous solution comprising Fe 3 O 4 , water and an acid to form a hydrolyzed silane solution, wherein a molar ratio of the hydrolysable aryl silane to the Fe 3 O 4 ranges from 100:1; mixing the hydrolyzed silane solution with a hydroxide base to form a precipitate; and recovering Fe—HSS from the precipitate. 19 . The method of claim 18 , wherein the hydrolyzable aryl silane is trimethoxy(phenyl) silane and the hydroxide base is NH 4 OH. 20 . The method of claim 18 , wherein the precipitate is not calcined.
Nose · CPC title
Medicinal preparations containing inorganic active ingredients · CPC title
Agglomerates; Granulates; Microbeadlets {; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction (A61K9/20 takes precedence if the final form is a tablet; microspheres with drug-free outer coating, microcapsules A61K9/50; mixture of different granules, microcapsules, (coated) microparticles A61K9/5084; nanoparticles A61K9/51)} · CPC title
Iron; Compounds thereof · CPC title
Inorganic compounds · CPC title
Related publications grouped by family.
Answers are generated from the same data shown on this page.